# MonumenTAL-6: HCP commentary report

> 539 verified statements (334 from clinicians verified by NPI or staff page) from 42 commentary sources · 12 findings · updated Oct 31, 2026

## Report

- Trial: 64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom
- NCT ID: NCT06208150
- Registry: https://clinicaltrials.gov/study/NCT06208150
- Sponsor: Janssen Research & Development, LLC
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: talquetamab plus pomalidomide; talquetamab plus teclistamab
- Indication: relapsed or refractory multiple myeloma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: 1a9ff8de97c0fc1257820dae8de8798ac613757bec80c7f739d0c4db01274802

## Counts

- HCP commentary sources screened: 67
- Sources cited by verified statements: 43
- Verified statements: 539
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 334
- Findings: 12
- Named people in screened sources (unnamed speakers and accounts not counted): 41
- Voices cited: 39
- Cited voices identity-verified: 29
- Organisational or shared accounts (not counted as people): 6

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

MonumenTAL-6 asks whether talquetamab with teclistamab or pomalidomide delays progression versus standard triplets in relapsed or refractory myeloma after anti-CD38 antibody and lenalidomide exposure. Commentary comes from X posts, podcasts and YouTube discussions, including physicians in hematology and oncology. The discussion turns on who needs dual targeting, particularly in high-risk or visceral extramedullary disease, and whether finite bispecific treatment preserves benefit. Infection prevention and access to continuing immune support also shape questions about bispecific adoption.

## Open Medical Affairs question

Which patients need Tal-Tec rather than Tal-P, a single-agent bispecific, CAR T or a conventional alternative, and what duration and supportive-care burden make that choice acceptable?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Emphatic interim-result enthusiasm does not settle combination selection or establish superiority to every early-relapse option
- F2. BCMA-first preferences reflect GPRC5D tolerability concerns, with selective exceptions and differing assessments of reversibility
- F3. Infection risk makes prevention, replacement access and continuing supportive-care burden central to adoption
- F4. Finite duration and response-adapted spacing attract support, but the optimal stopping point and preserved benefit remain uncertain
- F5. Dual targeting draws particular interest in high-risk and visceral extramedullary disease, without answering who needs both agents
- F6. CAR T versus bispecific preferences differ with risk tolerance, disease tempo, fitness and the value placed on treatment-free time
- F7. Sequencing and bridging choices remain conditional on target exposure, manufacturing access, disease control and weak comparative evidence
- F8. Prior anti-CD38 exposure versus refractoriness changes comparator relevance, daratumumab reuse and interpretation of alternative bispecific evidence
- F9. Tal-P has a distinct development rationale; skepticism about adding pomalidomide to Tal-Dara does not negate it
- F10. Conventional triplets, transplant, ADCs and mechanism-switching alternatives remain selective options rather than uniformly displaced treatments
- F11. Community delivery depends on shared care, practical prophylaxis, monitoring infrastructure and access—not efficacy alone
- F12. Patient education, nutrition surveillance, specialist support and financial burden shape whether treatment remains acceptable

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 48 | 34 | 22 | 19 | recorded | 2 |
| F2 | 64 | 42 | 11 | 17 | recorded | 3 |
| F3 | 33 | 22 | 12 | 15 | recorded | 2 |
| F4 | 39 | 30 | 15 | 16 | recorded | 4 |
| F5 | 80 | 61 | 13 | 15 | recorded | 3 |
| F6 | 39 | 22 | 5 | 8 | recorded | 3 |
| F7 | 68 | 50 | 10 | 14 | recorded | 4 |
| F8 | 53 | 38 | 12 | 14 | recorded | 2 |
| F9 | 48 | 30 | 12 | 14 | recorded | 3 |
| F10 | 36 | 19 | 6 | 5 | none recorded | 2 |
| F11 | 25 | 17 | 7 | 5 | none recorded | 2 |
| F12 | 17 | 11 | 3 | 3 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 24 | 6 | 1 | 2 | 15 | 50 | 4 | 15 posts and articles, 7 podcasts and video | yes |
| F2 | 28 | 12 | 4 | 13 | 7 | 69 | 3 | 2 posts and articles, 9 podcasts and video | yes |
| F3 | 21 | 1 | 6 | 2 | 3 | 33 | 2 | 4 posts and articles, 8 podcasts and video | yes |
| F4 | 14 | 10 | 8 | 1 | 6 | 40 | 4 | 7 posts and articles, 8 podcasts and video | yes |
| F5 | 45 | 13 | 3 | 5 | 14 | 87 | 10 | 4 posts and articles, 9 podcasts and video | yes |
| F6 | 26 | 4 | 2 | 4 | 3 | 43 | 1 | 1 post or article, 4 podcasts and video | yes |
| F7 | 38 | 13 | 6 | 3 | 8 | 78 | 3 | 2 posts and articles, 8 podcasts and video | yes |
| F8 | 32 | 4 | 0 | 4 | 13 | 59 | 2 | 4 posts and articles, 8 podcasts and video | yes |
| F9 | 25 | 6 | 3 | 3 | 11 | 49 | 2 | 1 post or article, 11 podcasts and video | yes |
| F10 | 22 | 3 | 4 | 3 | 4 | 38 | 1 | 1 post or article, 5 podcasts and video | yes |
| F11 | 13 | 1 | 6 | 2 | 3 | 27 | 2 | 3 posts and articles, 4 podcasts and video | yes |
| F12 | 12 | 0 | 1 | 0 | 4 | 21 | 1 | 3 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Progression Free Survival (PFS): F1 (9 shared claims), F9 (1 shared claims)
- Secondary endpoints: F1 (5 shared claims)
- Population and setting: F1 (1 shared claims), F5 (3 shared claims), F6 (2 shared claims), F7 (2 shared claims), F8 (11 shared claims)
- The comparison: F1 (3 shared claims), F5 (1 shared claims), F6 (1 shared claims), F8 (6 shared claims), F9 (5 shared claims), F10 (1 shared claims)
- Safety and tolerability: F1 (3 shared claims), F2 (14 shared claims), F3 (3 shared claims), F4 (2 shared claims), F5 (1 shared claims), F6 (1 shared claims), F8 (1 shared claims), F9 (1 shared claims), F12 (1 shared claims)
- Design and conduct: F1 (3 shared claims), F4 (1 shared claims), F8 (2 shared claims), F9 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F4. Finite duration and response-adapted spacing attract support, but the optimal stopping point and preserved benefit remain uncertain

An X thread asked whether talquetamab should be given for a defined maximum duration, in connection with MonumenTAL-6.

Source: X thread, 2026-06-13.

### F8. Prior anti-CD38 exposure versus refractoriness changes comparator relevance, daratumumab reuse and interpretation of alternative bispecific evidence

A podcast discussion asked whether MajesTEC-3 findings apply at first or second relapse after anti-CD38 exposure or in anti-CD38-refractory disease.

Source: podcast, 2026-09-03.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 20 sections | Paid |
| Verified statements with short source quotes and links | 539 | Paid |
| Trial aspects mapped | 16 | Free |
| Sources with links | 43 | Counts free |
| Speaker attribution for cited voices | 39 | Paid |

## Trial aspects

16 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression Free Survival (PFS) | discussed | 10 | 8 |
| Secondary endpoints | discussed | 5 | 5 |
| Population and setting | discussed | 18 | 10 |
| The comparison | discussed | 16 | 9 |
| Safety and tolerability | discussed | 24 | 11 |
| Design and conduct | discussed | 7 | 7 |
| Infection prevention and the burden of ongoing immune support | discussed | 28 | 11 |
| Finite duration, treatment cessation and response-dependent dose spacing | discussed | 36 | 15 |
| Selective dual targeting for high-risk and visceral extramedullary disease | discussed | 35 | 9 |
| Choosing CAR T or a bispecific at the relapse decision | discussed | 33 | 5 |
| Antigen sequence, holding treatment and bridging before or after CAR T | discussed | 51 | 10 |
| Anti-CD38 refractoriness, comparator suitability and alternative-study interpretation | discussed | 51 | 13 |
| Tal-P rationale versus the incremental value of an IMiD or CELMoD on another backbone | discussed | 38 | 11 |
| Selective conventional, transplant and ADC alternatives | discussed | 36 | 6 |
| Community access, step-up dosing, CRS prevention and restarting treatment | discussed | 27 | 8 |
| Patient education, nutrition, referrals and practical support | discussed | 18 | 4 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 50 | 28 |
| Podcasts | 7 | 7 |
| YouTube | 7 | 7 |
| Bluesky threads | 3 | 0 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2024-01-08 to 2026-10-29
- Cited window: 2024-01-08 to 2026-10-29
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: 64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom
- Registry: NCT06208150 (https://clinicaltrials.gov/study/NCT06208150)
- Study IDs: 64407564MMY3009 · 2022-502446-27-00 (EUCT number)
- Sponsor: Janssen Research & Development, LLC
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 838 (actual)
- Start: 2024-01-22 (actual)
- Primary completion: 2026-04-01 (actual)
- Primary endpoint: Progression Free Survival (PFS) (Up to 3 years 5 months)
- Intervention: Talquetamab (drug)
- Intervention: Pomalidomide (drug)
- Intervention: Teclistamab (drug)
- Intervention: Elotuzumab (drug)
- Intervention: Dexamethasone (drug)
- Intervention: Bortezomib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
- Not yet captured in this edition: a view on one-time cellular therapy versus continuous bispecific treatment and their quality-of-life trade-offs in relapsed myeloma.
- Not yet captured in this edition: a view on strict infection precautions qualifying the practical accessibility of bispecific treatment in early-relapse myeloma.
- Not yet captured in this edition: a view on belantamab alternatives when eligibility, infection risk or access limits T-cell-directed treatment in early relapsed myeloma.
- Not yet captured in this edition: a view on multi-antigen targeting in later-line myeloma and uncertainty about durability, resistance prevention and cure.
- Not yet captured in this edition: a remark on separately presented evidence for one-time cellular therapy versus continuous bispecific treatment in relapsed or refractory myeloma.
- Not yet captured in this edition: a view on strict infection precautions despite the feasibility of delivering bispecific treatment in any center, including early relapse.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 257 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are not a representative sample of all HCP opinion. Searches emphasized the trial identifier and recognized names, so discussion that never named the trial, used different terminology or appeared outside those searches may be missing. Some potentially relevant passages were not fully assessed; absence from this report should not be read as absence of a view.
- No full publication for NCT06208150 was discovered, and no protocol document was available from ClinicalTrials.gov. The July 2026 topline discussion described a first interim analysis without a congress presentation, trial-specific safety detail or disclosed data cutoff at that time. The released OS estimate lacked a confidence interval and p-value in that account. These limits constrain interpretation of both enthusiasm and adoption concerns.
- Statements span different interviews, posts, development stages and clinical settings. An account of ongoing recruitment, completed accrual, anticipated results or future approval describes that source’s setting; dates alone do not establish a change of mind or disagreement.
- MonumenTAL-2, RedirecTT-1, MonumenTAL-3, MajesTEC-3, MajesTEC-9 and CAR T studies inform the discussion but are not MonumenTAL-6 results. Their populations, regimens, dosing, follow-up and comparators differ. Informal comparisons and sequencing observations do not establish head-to-head superiority or an optimal sequence.
- Some spoken numerical accounts remain ambiguous or inconsistent. These include a high-risk control estimate, a 12-month PFS description in the ReDIRECT TT1 discussion, comparator labels differing from the registered EPd/PVd comparison, and an account of death-risk reduction that differs from the OS HR reported elsewhere. The report preserves those accounts as attributed statements rather than reconciling them into new estimates.
- Reposts, quoted posts, press-release summaries and media digests are not additional independent clinical endorsements. Organizations and automated accounts are distinguished from HCPs, and another party’s findings or opinion remain attributed to that party when relayed.
- Four speakers are described in the sources as involved in MonumenTAL-6. Their statements are not treated as independent external assessments or given additional evidentiary weight because of that involvement.
- Several discussion passages cannot be assigned to a named speaker. Their views remain attributed to the episode or discussion, without assuming that they represent a new participant, a separate endorsement or disagreement with another person in that source.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Some passages describe personal treatment experience or relay an unnamed oncologist’s reasoning. They provide patient-support and treatment-decision context, not separately identified direct HCP testimony or comparative outcome evidence.
- Toxicity assessments are not uniform. Some accounts emphasize improvement with dose modification or holds, while others emphasize persistent symptoms or events unresolved at a study cutoff. Different studies, follow-up and individual experiences should not be collapsed into either universal reversibility or permanent irreversibility.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Deep (539 verified statements)
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (29 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/monumental-6-nct06208150
- Agents: POST https://www.erudio.com/api/orders with {"report": "monumental-6-nct06208150", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=monumental-6-06208150

## Cite

Erudio Health. MonumenTAL-6 (NCT06208150): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/monumental-6-nct06208150

## Machine access

- JSON: https://www.erudio.com/reports/monumental-6-nct06208150.json
- Markdown: https://www.erudio.com/reports/monumental-6-nct06208150.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "monumental-6-06208150"}`